肺动脉高压（pulmonary hypertension，PH）是一组多因素引起的疾病，其特征是在静息状态下肺动脉平均压（mPAP）升高。值得注意的是，即使是轻度肺动脉高压，也与增加的死亡风险以及过早的死亡风险相关。然而，这一疾病往往隐匿且难以察觉，许多患者直至病情晚期才得以诊断。鉴于肺动脉高压的诊断和管理挑战，今年的ESC大会将通过摘要报告、研讨会、电子海报以及与欧洲呼吸学会的联席会议等多种形式，深入探讨肺动脉高压的先进诊断技术、个性化管理全过程、最新药物治疗进展以及其未来管理的方向。让我们共同关注即将在ESC 2024（欧洲心脏病学会年会）上展开的关于肺动脉高压的核心议题与重要议程，以期更全面地了解这一领域的最新进展与未来趋势。
Abstract Sessions
摘要报告
北京时间：8月30日 22:45-23:05
Pulmonary hypertension: advanced diagnostics
肺动脉高压：先进的诊断技术
Multiscan-PH: a multimodal deep learning approach for enhanced screening of pulmonary hypertension
Multiscan-PH：一种用于增强肺动脉高压筛查的多模态深度学习方法
Circulating Angiopoietin-2 (Angpt2) levels predict diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
循环血管生成素-2（Angpt2）水平预测慢性血栓栓塞性肺动脉高压（CTEPH）的诊断
TAPSE/sPAP by echocardiography to detect elevated pulmonary vascular resistance> 4 WU in postcapillary pulmonary hypertension patients: insights from the French PH HF registry
通过超声心动图检测TAPSE）/sPAP，以检测毛细血管后肺动脉高压患者的肺血管阻力升高（>4WU）：来自法国PH HF登记处的见解
Advancing pulmonary hypertension early detection through deep-learning enhanced chest radiographic analysis
通过深度学习增强的胸部X光分析推进肺动脉高压的早期检测
Assessment of sub clinical right ventricular ischemia using oxygen sensitive cardiac magnetic resonance imaging in patients with systemic sclerosis: mechanistic insights from advanced cardiac imaging
使用氧敏心脏磁共振成像评估系统性硬化症患者亚临床右心室缺血：来自高级心脏成像的机制见解
The pregnant patient with pulmonary arterial hypertensionand her offspring in the current era. Time to take into account the vasoreactive profile
当今时代肺动脉高压孕妇及其后代：是时候考虑血管反应性特征了
北京时间：8月31日 22:57
Right atrial and ventricular function in risk stratification of patients with pulmonary artery hypertension
右心房和心室功能在肺动脉高压患者风险分层中的应用
北京时间：8月31日 20:25
RKER-012， a novel modified ActRIIB ligand trap， attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertension
RKER-012，一种新型改良的ActRIIB配体陷阱，在肺动脉高压临床前模型中减轻了右心室心肌病
北京时间：9月1日 17:10
The impact of the 2022 definition of pulmonary hypertension on long-term clinical outcomes in patients with heart failure with preserved ejection fraction
2022年肺动脉高压定义对射血分数保留的心力衰竭患者长期临床结果的影响
北京时间：9月2日 21:50
Parathyroid hormone exacerbates pulmonary hypertension via parathyroid hormone receptors on pulmonary artery smooth muscle cells
甲状旁腺激素通过肺动脉平滑肌细胞上的甲状旁腺激素受体加重肺动脉高压
Symposium
研讨会
北京时间：8月30日 15:15-16:27
Pulmonary hypertension: from diagnosis to personalised care
肺动脉高压：从诊断到个性化管理
What’s hot in pulmonary hypertension?
肺动脉高压领域的热门话题
Not all pulmonary arterial hypertension (PAH) patients are young women
并非所有肺动脉高压（PAH）患者都是年轻女性
Obesity and pulmonary hypertension
肥胖与肺动脉高压
Personalising treatment of chronic thromboembolic pulmonary hypertension (CTEPH): right treatment for the right patient
慢性血栓栓塞性肺动脉高压（CTEPH）的个性化治疗：为合适的患者提供正确的治疗
Pulmonary hypertension: from diagnosis to personalised care - discussion
肺动脉高压：从诊断到个体化治疗的讨论
Official Joint Session
与欧洲呼吸学会的联席会议
北京时间：9月1日 18:00-18:45
Shaping the future management of pulmonary hypertension
塑造肺动脉高压的未来管理
Inclusion of the patient perspective in new trials in pulmonary hypertension
在肺动脉高压的新试验中纳入患者视角
Novel concepts in trial design: a trialist's view
试验设计的新理念：试验者的视角
Will omics finally fulfil the promise of personalised medicine in pulmonary hypertension?
组学技术最终能否实现肺动脉高压个性化医疗的承诺？
What is the state of the art of reverse remodelling strategies for the treatment of pulmonary arterial hypertension?
用于治疗肺动脉高压的反向重塑策略的最新进展
Moderated ePosters
电子海报展示
北京时间：8月30日 15:00
Association of Vascular endothelial factor D with pulmonary hypertension in heart failure: the PREHOSP-CHF Study
血管内皮因子 D 与心力衰竭肺动脉高压的关联：PREHOSP-CHF 研究
北京时间：8月30日 18:00
Novel CMR-assessed right ventricular-pulmonary artery coupling index independently associates with exercise capacity and clinical risk in pulmonary arterial hypertension
新型 CMR 评估的右心室-肺动脉耦合指数与肺动脉高压的运动能力和临床风险独立相关
北京时间：9月2日 00:00-00:50
Pulmonary hypertension: insights from registries， retrospective data sets， and meta-analyses
肺动脉高压：来自注册机构、回顾性数据集和荟萃分析的见解
Improving morbidity and mortality in patients with pulmonary hypertension: insights from a nation-wide registry
改善肺动脉高压患者的发病率和死亡率：来自全国登记处的见解
Real-world evidence on pulmonary arterial hypertension: interim analysis from the Italian observational study INSPECTIO
肺动脉高压的真实世界证据：来自意大利观察性研究 INSPECTIO 的中期分析
Idiopathic pulmonary arterial hypertension， associated with connective tissue disease and comorbidities: prognostic differences? Results the Spanish Registry of pulmonary hypertension (REHAP Registry)
特发性肺动脉高压，与结缔组织疾病和合并症有关：预后差异？西班牙肺动脉高压登记册（REHAP登记册）的结果
Clinical， echocardiographic and haemodynamic predictors of morbidity and mortality in pulmonary hypertension: a nation-wide registry
肺动脉高压发病率和死亡率的临床、超声心动图和血流动力学预测指标：一项全国性登记研究
The importance of comorbidities in idiopathic and associated with connective tissue disease pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)
合并症在特发性肺动脉高压和与结缔组织疾病相关的肺动脉高压中的重要性：来自西班牙肺动脉高压登记处的数据
A systematic review and meta-analysis of health-related quality of life (HRQoL) outcomes in randomised controlled trials for pulmonary arterial hypertension (PAH)
肺动脉高压随机对照试验中健康相关生活质量（HRQoL）结果的系统评价和荟萃分析
Changing patterns in clinical， echocardiographic and haemodynamic characteristics ， and management strategies that may be translated to improved survival in pulmonary hypertension
改变临床、超声心动图和血流动力学特征的模式，以及可能转化为提高肺动脉高压生存率的管理策略
Risk prediction and survival in elderly patients with pulmonary arterial hypertension: data from the hellenic pulmonary hypertension registry (HOPE)
老年肺动脉高压患者的风险预测和生存：来自希腊肺动脉高压登记处（HOPE）的数据
Mini nutritional assessment is a predictor of mortality and morbidity in patients with pulmonary arterial hypertension
微型营养评估是肺动脉高压患者死亡率和发病率的一个预测指标
北京时间：9月1日 18:00
Colchicine as a therapeutic option for the treatment of pulmonary arterial hypertension (PAH) in a rat model
秋水仙碱作为大鼠模型中肺动脉高压（PAH）治疗的选择
北京时间：9月2日 21:00-21:50
Current pharmacological treatments for pulmonary hypertension
目前肺动脉高压的药物治疗
Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL)
β阻滞剂对有和没有合并症的PAH患者预后的影响：一项多中心前瞻性队列研究（BNP-PL）
Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension
ARNI和SGLT2i联合用药对三尖瓣反流峰值速度和肺动脉高压超声心动图可能性的影响
The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials
曲前列尼尔治疗肺动脉高压的安全性和有效性：随机对照试验的系统评价和荟萃分析
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
selexipag 三联序贯联合疗法在肺动脉高压患者中的疗效和耐受性：来自单中心研究的见解
Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre， double-blinded， randomised， placebo-controlled trial
艾森曼格综合征（MINES）患者的美托洛尔治疗研究：一项单中心、双盲、随机、安慰剂对照试验
Real-world evidence of upfront riociguat plus endothelin receptor antagonist combination therapy in pulmonary arterial hypertension
肺动脉高压患者使用利奥西呱联合内皮素受体拮抗剂组合疗法的真实世界证据
Efficacy of specific drug class therapy in pulmonary arterial hypertension associated with HIV， portal hypertension or both: a single Center experience
特定药物类别治疗HIV相关肺动脉高压、门静脉高压或两者兼有患者的疗效：单中心经验
Cardiopulmonary exercise testing in long-term calcium channel blockers responders， does it normalize in the same way as pulmonary vascular resistance?
长期钙通道阻滞剂应答者的心肺运动试验，是否与肺血管阻力相同？
Positioning Imatinib for Pulmonary Arterial Hypertension (PIPAH) study
伊马替尼治疗肺动脉高压（PIPAH）研究
Impact of new definition on the prognosis of patients with pulmonary hypertension compared to classic definition
与经典定义相比，新定义对肺动脉高压患者预后的影响
北京时间：9月2日 21:00
A novel nurse-led， multidisciplinary， and guideline-directed disease intensive management program improves long-term survival of pulmonary hypertension patients
一项由护士主导、多学科合作、遵循指南的疾病强化管理计划改善了肺动脉高压患者的长期生存率